Introduction
Over the past two decades, the life expectancy of patients living with HIV has significantly increased, which can be mainly ascribed to the potency of combined ART (cART). Numerous drugs have been developed over this period, including new classes of cART such as PIs, integrase strand transfer inhibitors (INSTIs) or new drugs within the 'historical' classes of NRTIs and NNRTIs, which have offered new long-term benefits against MDR viruses. For many HIV-infected people, the infection has now transformed into a chronic manageable infection. 1 The common highly active antiretroviral regimen recommended worldwide remains a backbone combination of two NRTIs associated with a third antiretroviral drug, with a preference for a PI boosted with ritonavir (PI/r), an NNRTI or, more recently, an INSTI. 1, 2 While achieving a sustained virological suppression remains a challenge for many HIV-infected patients, the risk and potential adverse events associated with long-term cART have become a major issue. 3 In that respect, several strategies aimed to lighten the antiretroviral regimen without jeopardizing future treatment options have been explored. 1 Less-drug regimen (LDR) is defined as a reduction of the number of antiretroviral drugs, which includes de-escalation to a dual regimen or even a monotherapy. It is important to distinguish LDR from dose reductions based on pharmacokinetics parameters with no expected impact on drug exposure, and from simplification with a single tablet regimen (STR) that refers to a decrease in the number of pills, but not of drugs. The switch from a PI/ r-containing regimen to a regimen containing an unboosted PI is another option for the LDR-oriented strategy. Such an option may be relevant when considering the impact of ritonavir on the deleterious effects of PI per se on lipid metabolism depending on the dose administered as a booster, 4, 5 as well as the impact on drug -drug interactions in a population expected to exhibit more age-related comorbidities. Thus, two main antiretrovirallightening strategies can be considered, i.e. (i) 'NRTI sparing', consisting of dual therapy or monotherapy, and (ii) 'boost sparing', for PI-containing regimens.
Several dual therapies have been assessed in maintenance strategies with different results in terms of virological efficacy and toxicity concerns, depending on the type of combination. resistance, PIs may be preferentially used when a reduction of drugs is considered in patients with virological suppression. In that respect, the European AIDS Clinical Society (EACS) retains dual therapies with atazanavir/ritonavir or lopinavir/ritonavir as possible options in switch strategies for patients with virological suppression. 2 This position is mainly based on data available from randomized studies in maintenance therapy assessing the association of lamivudine with lopinavir/ritonavir 7 or atazanavir/ ritonavir. 8 -10 Results from pilot studies on the association of raltegravir with lopinavir/ritonavir, 11 darunavir/ritonavir 12 or atazanavir/ritonavir, 13 appear limited in terms of the number of patients assessed.
Different randomized clinical trials also explored the efficacy of PI/r monotherapy in patients with viral suppression with encouraging but controversial results regarding the increased risk of virological rebounds.
14,15 A meta-analysis based on 13 randomized trials suggests a higher risk of plasma HIV-1 RNA increase, but with no risk of treatment-induced drug resistance. 16 While some experts retain PI/r monotherapy as a possible option for maintenance therapy in patients with virological suppression, 17 it is generally recommended to avoid this option for the benefit of dual therapy and to restrict it to patients with intolerance to NRTIs. 1 -3 The withdrawal of ritonavir used as a PI booster in patients with virological suppression on cART, including a PI/r, can also be considered as a switch to an LDR according to the definition stated above. Concerning a switch to unboosted PI-containing regimens, only atazanavir-based combinations appear as possible options, which have been assessed in a maintenance setting. 18 Overall, atazanavir appears as the most documented PI in terms of LDR in maintenance therapy in patients virologically suppressed, either as part of a dual therapy (particularly with lamivudine) or as a non-ritonavir-boosted PI.
Atazanavir was approved 10 years ago as a third agent in combination with the two NRTI backbones recommended and widely used, i.e. tenofovir disoproxil fumarate/emtricitabine or abacavir/ lamivudine, two combinations available as STRs to improve patient convenience and adherence. In an induction setting, the recommended once-daily dose of atazanavir is 300 mg when used with 100 mg ritonavir, and 400 mg when used without ritonavir.
1,2 The drug is available in capsules of 150, 200 or 300 mg, which confers flexibility in terms of dose adjustment when required (e.g. hepatitis C virus coinfection and women of childbearing age using hormonal contraceptives). 1, 2, 19 Based on extensive data on atazanavir obtained in several settings, including dual therapies and unboosted atazanavir as a third agent, the aim of this paper is to focus on the relevance of atazanavir-based lightened regimens in terms of expected sustained virological suppression, genetic barrier and risk of emerging resistance, and drug -drug interactions. The expert opinion presented herein also addresses the situations that may be concerned with a switch to PI-based LDR.
Results of studies assessing atazanavir/ ritonavir or atazanavir in LDR
The selected studies include those published in international reviews (indexed in the PubMed database) as well as abstracts presented at international congresses over the past 5 years. Both cross-sectional (comparative or not) and retrospective studies have been taken into account. The PubMed research was based on keywords including 'HIV', 'antiretroviral', 'de-escalation', 'dual therapy' and 'monotherapy' and was restricted to 'clinical trials' published over the past 10 years.
Overview of clinical data on unboosted atazanavir in association with NRTIs
Several studies have assessed the feasibility of switches to unboosted atazanavir in patients exhibiting virological suppression. The SWAN 20 and SLOAT 21 randomized open studies included antiretroviral-experienced HIV patients given a two NRTI-based regimen containing a PI/r at the time of screening, mainly (SWAN) or exclusively (SLOAT) lopinavir/ritonavir. NRTI-based regimens mostly included tenofovir disoproxil fumarate in the SLOAT study, while tenofovir disoproxil fumarate accounted for ,10% in the SWAN study. The mean exposure to cART was 3 years in both studies. In the SLOAT trial, patients in the control groups continued their previous regimen including lopinavir/ritonavir, while in the SWAN trial PI/r was replaced with atazanavir/ritonavir. In both studies, the proportion of virological rebound after 48 weeks of follow-up was similar in the control groups and in the unboosted atazanavir groups, which showed the non-inferiority of the atazanavir-containing regimen. However, lipid plasma parameters, including total cholesterol and triglycerides, were significantly improved in patients randomized to receive unboosted atazanavir. Both studies suggest that switching lopinavir/ritonavir to atazanavir in patients with virological suppression can be expected to improve tolerability without challenging the antiretroviral efficacy of the regimen. In the SLOAT trial, resistance analysis showed that among the five patients who failed on unboosted atazanavir, only two harboured primary resistance mutations (versus three of seven in the atazanavir/ritonavir group). All of them had previously failed other PIs, generally indinavir and/or nelfinavir. According to the French HIV drug resistance interpretation algorithm (updated in September 2015), mutations conferred resistance to lopinavir/ritonavir and atazanavir/ritonavir (L10I, L90M, A71I and L90M mutations) in one patient, while they were only associated with resistance to 800/100 mg darunavir/ritonavir once daily (but not to 600/100 mg darunavir/ritonavir twice a day) in the other one.
The ASSURE trial assessed the effect of switching atazanavir/ ritonavir to atazanavir in patients having received atazanavir/ ritonavir associated with tenofovir disoproxil fumarate/emtricitabine for .3 years. 22 In that study, the NRTI backbone was different in the groups of patients receiving atazanavir (backbone switched for abacavir/lamivudine) or atazanavir/ritonavir (tenofovir disoproxil fumarate/emtricitabine maintained). After 48 weeks, the proportion of patients with an undetectable plasma viral load (,50 copies/mL) was 87% in both arms. The type and frequency of adverse events grades 2 -4 were similar. However, total bilirubinaemia was significantly higher in the group receiving tenofovir disoproxil fumarate/emtricitabine associated with atazanavir/ritonavir, and bone-and kidney-related markers showed a more favourable profile in the group receiving abacavir/lamivudine associated with unboosted atazanavir. This study suggests that the benefits observed with unboosted atazanavir in terms of tolerance could be enhanced when associated with an NRTI regimen not containing tenofovir disoproxil fumarate, even For debate though it is considered as the preferred NRTI in European and American guidelines in triple therapy. 1, 2 The feasibility of switching to unboosted atazanavir has also been studied in patients having undergone an initial induction phase (.6 months) with a regimen containing atazanavir/ritonavir associated with two NRTIs not containing tenofovir disoproxil fumarate. In the ARIES trial, 23 the NRTI backbone consisted of abacavir/lamivudine in half of the population, while in the INDUMA trial, 24 all the patients received abacavir/lamivudine. In both studies, the rate of viral suppression ( 80%) and CD4+ levels at 48 weeks were similar in patients having received boosted atazanavir or not. The maintained viral suppression in patients switched to unboosted atazanavir was still observed at 144 weeks in the extension phase of the ARIES study. 25 Overall, the rates of adverse events were similar, while lipid parameters, particularly triglycerides, were improved in patients switched to atazanavir. Regarding the possible emergence of resistance in patients exhibiting virological failure, both studies found no major mutations in patients switched to unboosted atazanavir. In the ARIES trial, the two patients of the atazanavir group who met virological failure had one emergent minor HIV protease mutation (A71T or L10F), with no change in phenotypic susceptibility to any drug, 23 while one major protease mutation (N88S) was found in one patient of the control arm. In the INDUMA trial, no phenotypic resistance to atazanavir or other PIs was found in patients having failed. 24 The five studies cited above were selected for a meta-analysis aimed to evaluate the clinical evidence of switching ritonavirboosted PI to atazanavir. 18 The analysis clearly showed a significant decrease in the risk ratio (RR) of hyperbilirubinaemia grades 2 -4 (RR¼ 0.43; 95% CI ¼ 0.21-0.89; P ¼ 0.02) consecutive to the atazanavir plasma exposure decrease, but with no statistically significant impact on virological efficacy (defined as plasma HIV-RNA ,50 copies/mL) between regimens (RR ¼ 1.04; 95% CI ¼ 0.99 -1.10), with no heterogeneity (I 2 ¼ 0%). This analysis reinforces individual data and demonstrates that replacing a PI/ r (including atazanavir/ritonavir) with atazanavir is expected to improve lipid parameters and bilirubin levels without sacrificing virological suppression or immune status. The feasibility of this approach is also supported by real-life data retrospectively obtained from a European cohort including 10 centres and 886 patients with a plasma viral load ,50 copies/mL on ART, and who had been switched to unboosted atazanavir associated with two NRTIs (mainly including abacavir or tenofovir disoproxil fumarate) between January 2002 and December 2008. 26 The probability of virological failure at 3 years was 20%. Among the patients without a prior history of virological failure (defined by two consecutive plasma HIV-1 RNA levels ,50 copies/mL), only hepatitis C virus coinfection was associated with the risk of virological failure [HR ¼ 2.25 (1.10 -4.60); P, 0.026]. In the same multivariate analysis, abacavir use was associated with a significantly lower risk of virological failure [HR ¼ 0.43 (0.19 -0.96); P,0.040]. Furthermore, patients who switched had a satisfactory safety profile, with a relevant improvement of lipid plasma parameters as shown by a decrease in total cholesterol (79%) and triglycerides (21%) over a 12 month period.
The data mentioned above, based on robust long-term randomized trials 18 and reinforced by a multicentre European cohort, 26 support the feasibility of switching a drug regimen containing PI/r to a regimen containing two NRTIs associated with unboosted atazanavir. It is noteworthy that such a lightening-oriented switch was found virologically effective whatever the associated NRTI backbone, which suggests that changing tenofovir disoproxil fumarate/emtricitabine for abacavir/lamivudine does not jeopardize the sustained virological suppression. Interestingly, better outcomes in terms of bone-or kidney-related markers were noted when atazanavir was associated with abacavir, which may be very relevant in the context of a tenofovir disoproxil fumarate-sparing strategy aimed at reducing the risks of renal toxicity. Furthermore, no increase in cardiovascular biomarkers of inflammation and thrombogenesis was found in patients switched to atazanavir associated with abacavir/lamivudine. 22 The general conclusions from the studies assessing unboosted atazanavir suggested that there was no difference in the rate of drug resistance mutations for patients receiving atazanavir compared with those receiving a combination with PI/r, 18 suggesting a very low risk of emergence of protease mutations in patients switched to unboosted atazanavir. In this respect, an Italian cohort of 249 patients on a triple regimen including two NRTIs and unboosted atazanavir followed over a median time of 3 years showed that the sustained virological efficacy of the regimen was coupled with a good profile of tolerance, and that the emergence of mutations only concerned patients exhibiting multiresistance to NRTIs. 27 Besides, the presence of M184V before the switch was not associated with a risk of failure.
Several previous studies have raised the discussion about maintaining plasma HIV-RNA ,1 copy/mL, as it could have a putative effect on cardiovascular disease-associated markers. 28 A retrospective study presented during the EACS 2015 meeting showed that switching atazanavir/ritonavir (300/100 mg once daily) to unboosted atazanavir (400 mg once daily) in combination with tenofovir disoproxil fumarate/emtricitabine or abacavir/lamivudine allows maintaining plasma viral load ,1 copy/mL during 12 months. 29 This is a further argument to consider unboosted atazanavir as a potent therapy when used in treated patients harbouring a fully suppressed plasma viral load.
Based on the comparable level of virological suppression, a similar lack of treatment-emergent mutations and an improved tolerance regarding lipid profiles (decrease in triglycerides and of total and LDL cholesterol) and bilirubin levels, the maintenance on a triple therapy including two NRTIs and unboosted atazanavir is considered as a possible alternative switch strategy for patients with virological suppression. 1, 2 According to the comparative studies described above, the possibility of switching to a regimen of atazanavir plus abacavir/lamivudine is considered relevant in patients with virological suppression exhibiting adverse effects from tenofovir disoproxil fumarate or ritonavir. 1 Overview of the clinical data on atazanavir/ ritonavir-based dual therapy
The most extensively studied dual associations include atazanavir/ritonavir associated with lamivudine and, to a lesser extent, atazanavir or atazanavir/ritonavir associated with raltegravir.
Two main randomized open-label studies have compared the maintenance of a triple therapy including atazanavir/ritonavir to a switch to a dual therapy of atazanavir/ritonavir and lamivudine. 9, 30 The randomized ATLAS-M study was undertaken after a pilot single arm study in 40 patients with virological suppression for .3 months had shown a sustained efficacy during at least For debate JAC 48 weeks with the dual therapy. 30 The ATLAS-M study included 266 patients randomized to receive the same triple therapy including two NRTIs associated with atazanavir/ritonavir, or to be switched to the dual therapy. 8 The mean period on cART was 20 months and the nadir CD4 ranged between 119 and 367 cells/ mm 3 (median 270 cells/mm 3 ). The NRTI backbone prior to randomization (and in the control arm) mainly included tenofovir disoproxil fumarate (79% of the patients). In terms of efficacy, the proportion of patients free of treatment failure at 24 weeks was similar in the groups on triple (85%) or dual (92%) therapy. Interestingly, the gain of CD4 counts over the 24 week study period was significantly more marked in the dual therapy group (+90 versus +10 cells/mm 3 ; P ¼ 0.007), however, the clinical relevance of such a difference remains questionable, as was the mechanistic explanation. Regarding tolerance, the renal function assessed by the MDRD-based estimated glomerular filtration rate was significantly improved in the group of patients switched to atazanavir/ ritonavir and lamivudine (+5.00 versus 22.85 mL/min/1.73 m 2 ; P ¼ 0.001). No difference between the two groups emerged regarding overall adverse events or laboratory toxicities.
The similarly designed multicentre open-label SALT trial aimed to determine whether atazanavir/ritonavir associated with lamivudine is inferior or not to atazanavir/ritonavir associated with two NRTIs in 286 HIV-positive patients with virological suppression on a stable three-drug regimen for .1 year [28 months ]. 9 In that study, the nadir CD4 ranged between 108 and 318 cells/mm 3 (median: 212 cells/mm 3 ). A 4 week period on two NRTIs associated with atazanavir/ritonavir preceded the randomization to the same triple therapy or to dual therapy including atazanavir/ ritonavir and lamivudine. At 48 weeks, the virological efficacy shown in the ATLAS-M study was confirmed, with no statistical difference between the triple (78%) and dual (84%) therapies. However, only a slight non-significant difference in the change of CD4 was observed in favour of the dual therapy (+11 versus 211 cells/mm 3 ; P ¼0.45), while the basal CD4 counts were similar to that reported in the ATLAS-M trial ( 580 cells/mm 3 in both studies). Only five and four virological failures were reported in the dual and triple therapy groups, respectively. One patient on triple therapy developed a resistance mutation M184V. No NRTI or PI resistance mutations were documented in the atazanavir/ritonavir and lamivudine arm. In terms of toxicity, changes in renal function, bone density and fat gain/distribution were statistically similar between groups. However, it is noteworthy that three of the 10 discontinuations reported in the triple therapy arm were linked to renal toxicity (n ¼ 2) or nephrolithiasis (n ¼ 1) patients. None of the three discontinuations reported in the dual therapy group (two for hyperbilirubinaemia and/or ocular icterus and one for liver function test) were due to renal toxicity.
Taken together, the ATLAS-M and SALT studies clearly demonstrate that switching a triple therapy including two NRTIs and one PI/r to the dual association of atazanavir/ritonavir and lamivudine allows sustaining the virological efficacy with a benefit regarding tenofovir disoproxil fumarate-induced renal toxicity. Furthermore, updated data presented during the 2016 Conference on Retroviruses and Opportunistic Infections showed that sustaining virological suppression on atazanavir/ritonavir and lamivudine was associated with significant improvements in bone mineral density and markers of bone turnover, 31 and with stability of HIV-induced neurocognitive disorders 32, 33 at 48 and 96 weeks. On the other hand, absence of the emergence of major resistance mutations supports the feasibility of an association of atazanavir/ ritonavir and lamivudine in patients with virological suppression on triple therapy.
With the objective of assessing the efficacy of an NRTI-sparing dual therapy, atazanavir used with or without ritonavir has been evaluated in association with raltegravir. Pharmacokinetics studies of the association assessed as twice daily (400 mg raltegravir +300 mg atazanavir) or once a day (800 mg raltegravir +300/100 mg atazanavir/ritonavir) administrations have shown considerable pharmacokinetic variability for both atazanavir and raltegravir, demonstrating non-equivalence between atazanavir doses. 34 However, this preliminary study performed in 25 adults with undetectable viral load, which also assessed the plasma viral load, virological failures and CD4 counts over a 48 week period, suggested that in terms of efficacy, the association of raltegravir and atazanavir, boosted or not, was efficacious and safe in induction-maintenance therapy in patients with virological suppression, particularly in individuals with ART-related toxicities or risks. 34 The randomized HARNESS study assessed the efficacy and safety of the association of raltegravir twice a day and atazanavir/ritonavir once daily in comparison with the standard triple therapy including tenofovir disoproxil fumarate/emtricitabine associated with atazanavir/ritonavir in a maintenance setting in 109 patients with virological suppression after an induction period. 13 At 48 weeks, 78% and 86% of the patients in the dual and triple therapy groups, respectively, had completed the study. The corresponding proportion of patients with virological suppression (plasma HIV-RNA ,40 copies/mL) were 91% and 100% at both 24 weeks (primary endpoint) and 48 weeks, reflecting an equivalence of the two regimens. However, the rates of virological rebounds were higher in the dual therapy group (12.5% versus 2.7%). Genotypic resistances were found in two patients of the dual therapy group (none in the control group), one with a major resistance to INSTI (Y143C+ N155H) and one with both resistance to INSTI (F121Y) and multiresistance to PIs including atazanavir (L10V + L33F + M46L). The overall tolerance was similar in both groups with 19% and 14% of grade 3 -4 adverse events reported at 48 weeks in the dual and triple groups, respectively. These data are supported by another study showing that switching pretreated patients with undetectable viral load on standard triple therapy to atazanavir/ritonavir associated to raltegravir was just as efficient in terms of virological suppression at 48 weeks. 35 While preliminary results from a retrospective monocentric study suggest that dual therapy associating atazanavir (with or without ritonavir) and dolutegravir may also provide a high proportion of viral suppression in treatment-experienced patients, 36 dual associations of atazanavir/ritonavir with INSTIs in maintenance therapy remain to be more documented, particularly regarding the risk of resistance.
Who would be the patients suitable for atazanavir-based LDR?
Once the feasibility of lightened antiretroviral-based regimens has been demonstrated in terms of virological efficacy, sustained immune status and absence of resistance jeopardizing future options, the issue is the context in which such a switch deserves to be considered. Several parameters need to be taken into account including patient adherence to the strategy, duration of viral suppression, possible history of virological failure and For debate resistance mutations, immune status and history (nadir CD4), and possible co-medication or specific situations associated with pharmacokinetic issues. 37 Considering a switch to an LDR containing a PI in patients with virological suppression, the EACS guidelines retain three major criteria: undetectable viral load for at least 6 months; no resistance to PI; and absence of hepatitis B virus (HBV) coinfection. 2 Regarding the duration of suppressed viraemia before a switch may be considered, the EACS guidelines are most likely based on the inclusion criteria of studies having assessed the corresponding strategy. In studies of maintenance on unboosted atazanavir, 20 -24 the period with suppressed plasma HIV-RNA ranged between 3 and 6 months, with no apparent relation with virological or immune outcomes. However, one may also refer to the actual characteristics of the patients at baseline, which may be significantly different. In the dual therapy studies assessing switching to atazanavir/ritonavir and lamivudine, while inclusion criteria included plasma HIV-1 RNA ,50 copies/mL for 6 months or longer, patients included had actually experienced longer periods of virological suppression (at least 20 months). 8, 9 Thus, choosing an inclusion criterion rather than the actual status of evaluated patients is questionable. Furthermore, it has been shown that the risk of virological failure, when adjusted for adherence, declines with longer duration of continuous suppression 38 and that a median period of 9 months is required to reach levels of plasma HIV-RNA ,50 copies/mL on cART. 39 An observational study retrospectively assessing patients with virological suppression, then switched to PI/r monotherapy, showed that those with a duration of .12 months were less likely to experience virological failure. 40 This observation is consistent with the 9 month mean period supposed to allow reaching virological suppression on cART. 39 To minimize the risk of virological rebound, our group would retain a minimal period of 12 months with a sustained viral suppression before switching to a dual therapy, which must be individually challenged depending on each patient history. For instance, a longer period could be considered in patients who experienced a slow decrease in viral load before being not detectable by the routine tests used (threshold ,40 copies/mL or lower when available).
Another parameter known to determine the sustained virological response to antiretrovirals, not mentioned in the EACS guidelines, is the nadir CD4 counts, which may appear to be more relevant than current CD4 counts. Indeed, the multivariate adjusted analysis in the EuroSIDA cohort of patients on unboosted atazanavir associated with abacavir/lamivudine found an association between virological failure and nadir CD4 counts [HR ¼ 0.60 (0.39 -0.93) per 100 cells higher]. 41 In the SALT and ATLAS-M studies, which showed the efficacy of atazanavir/ritonavir and lamivudine as a dual therapy, the median nadir was between 200 and 300 cells/mm 3 . 9, 30 While values of nadir .200 cells/mm 3 could be recommended before switching to a PI/r monotherapy, a value .100 cells/mm 3 could appear acceptable to consider a switch to a dual therapy. The absence of encephalitis, which is supposed to be excluded when considering a nadir CD4 at least equal to 200 cells/mm 3 , should also be taken into account.
It is obvious that the absence of a previous virological failure and of mutations associated with an agent to be introduced in the LDR should be taken into account. This implies that an exhaustive therapeutic and virological history is available, which should eliminate possible resistance-associated mutations likely to decrease the virological efficacy of the regimen considered.
In summary, our group proposes a decision-making process based on answers to three questions to be addressed before reducing the number of treatment molecules: (i) Has the patient been virologically suppressed for at least 12 months on at least three active drugs?; (ii) Is the therapeutic and virological history of the patient exhaustively available?; and (iii) Can the absence of encephalitis history be ascertained? Our position is that for any situation in which the answer to each question is 'yes', the patient should be considered as a candidate for a switch to an LDR (Figure 1) . If a dual therapy is considered, it must be checked that the nadir CD4 is .100 cells/mm 3 or, if not available, that the patient did not experience previous opportunistic infections stage C of the CDC (excluding TB). Whatever the LDR considered (dual or including unboosted atazanavir), the absence of resistance to the drugs included in the LDR must be checked. Finally, negativity regarding HBV infection (absence of hepatitis B antigens) must be taken into account as soon as tenofovir disoproxil fumarate sparing is planned.
Such an individual-based strategy, aimed to alleviate or prevent ART-related toxicities, should necessarily take into account the level of expected adherence (particularly in patients previously treated with STR) and the co-medications to determine the time, feasibility and pharmacokinetic-related modalities of the maintenance regimen.
What is the expected impact of LDR on HIV reservoirs and patient monitoring?
It is admitted that in patients with HIV viral load undetectable in blood, infection persists in sanctuary areas such as the CNS, testicular and lymphoid tissues, where antiretroviral drug concentrations may decrease under a therapeutic level, which is associated with persistent immune activation. Thus, the possible risk associated with switching patients to LDR must be addressed, even though available data do not support a specific relationship. For instance, studies addressing cognitive impairment and persistent CNS injury in patients treated for HIV suggest that the HIV-induced cognitive impairment that can occur in patients on triple therapy is dependent on various factors including blood detectable viral load. 42 Besides, studies analysing dynamic and spatial processes involved in the replenishment of viral reservoirs in lymphoid tissue sanctuary sites suggest that the virus does not inevitably develop resistance because of the presence, although at lower concentrations, of antiretroviral drugs. 43 On the other hand, while testis represents a complex pharmacological compartment with the potential to limit the entry of antiretrovirals known to be substrates for the ATP-binding cassette transporters found in the testes, thus favouring HIV-1 persistence, a heterogeneity of antiretrovirals regarding testes/blood concentration ratios, including antiretrovirals of the same class, has also been shown. 44 Indeed, while similar plasma versus testicular concentrations were observed for tenofovir, lamivudine and emtricitabine, higher testicular concentrations were observed for ritonavir and lower testicular concentrations for efavirenz, atazanavir and darunavir. However, a clear difference was observed between atazanavir and darunavir with testes/blood concentration ratios 0.80 and 0.20, respectively, with darunavir concentrations For debate JAC falling below therapeutic values. Thus, lamivudine, ritonavir and atazanavir entries are expected to be not limited or poorly limited. Overall, studies addressing the source and impact of HIV reservoirs suggest that a switch to an LDR based on atazanavir and lamivudine is not expected to modify the long-term challenge of persistent immune activation and its potential impact on comorbidities. This statement is also supported by the analysis of patients included in the SALT study comparing switching therapy to dual therapy (atazanavir/ritonavir + lamivudine) or triple therapy (atazanavir/ritonavir +two NRTIs) showing that incidence rates of neurocognitive impairment or recovery were similar in the two groups. 45 On the other hand, one cannot exclude that HIV-DNA, as a reservoir of drug resistance mutations, might play a role in virological failures observed after switching to an LDR including unboosted atazanavir. While data are poor regarding this issue, some studies assessing dual therapies showed a persistence of undetectable levels in all the patients despite last HIV-DNA levels 3 log copies/10 6 PBMCs, 36 and that baseline HIV-DNA content correlated with the pre-cART viral load, but not with time with undetectable levels of HIV-RNA. 46 Thus, our position is that HIV-DNA levels have not to be considered as a limit to a switch to LDR due to the lack of related markers and defined cut-off, but that particular attention must be paid to patients exhibiting high levels at the time of the switch.
So far, no guidelines regarding laboratory monitoring have been specifically proposed in patients switched to LDR. The recommendations stating viral load and CD4 monitoring at intervals of 6 months once HIV-RNA is suppressed for 1 year and CD4 counts are stable 3 may then be considered, while this issue remains to be assessed and defined in a real-life setting. Whatever the switch strategy, the EACS states that patients should be seen within 4 weeks after the treatment switch to check for maintenance of suppression and possible toxicity of the new regimen 2 ; the American guidelines recommend a viral load test 4 -8 weeks after the switch to check for rebound viraemia. 1 Because switching to a dual therapy, including atazanavir/ritonavir and lamivudine, is not expected to jeopardize viral load suppression and alternative therapeutic options, we propose conventional laboratory monitoring at 1 month to check for rebound viraemia and compliance to the new therapy, which is a delay shorter than that recommended in American 1 and European 2 guidelines, and then after 3 months and every 6 months as recommended by the French guidelines. 37 
NRTI sparing or ritonavir sparing?
Switching an effective regimen to a triple therapy including unboosted atazanavir or a dual therapy with atazanavir/ritonavir is supposed to be guided by the objectives of the strategy and current regimen in terms of toxicities to be diminished or prevented.
Ritonavir per se is known to be associated with a modification of lipid parameters (increase in plasma total cholesterol, LDL cholesterol, total/HDL cholesterol ratio and triglycerides) even when used at a low dose, the effect being enhanced in association with PIs. 47, 48 Atazanavir is the only PI developed to be used with ritonavir at a booster dose or without ritonavir, and a review of the data cited above clearly showed that switching a PI/r-based triple therapy to a regimen containing unboosted atazanavir significantly improved the lipid profiles without compromising the For debate virological efficacy. A systematic review including nine randomized control trials comparing atazanavir or atazanavir/ritonavir to PI/r-based regimens (mostly including lopinavir/ritonavir, but not darunavir/ritonavir) concluded that plasma lipid concentrations at 48 weeks were lower with atazanavir/ritonavir than with another PI/r and that the improvement was clearly enhanced with unboosted atazanavir, with a significant reduction of total and non-HDL cholesterol at 48 weeks. 49 The long-term benefit of unboosted atazanavir associated with two NRTIs has been confirmed in the Italian cohort cited above, which showed a sustained virological efficacy coupled with a good profile of tolerance including an improvement of both total cholesterol and triglyceride levels. 27 Another important tolerance-related issue concerns hyperbilirubinaemia, known as a common adverse event correlated with atazanavir plasma concentrations. 50 Atazanavir is both a substrate and a competitive inhibitor of cytochrome P450 3A4 and a competitive inhibitor of the bilirubinconjugating enzyme UDP glucuronyltransferase 1A1. Atazanavir is metabolized and eliminated primarily by the liver and its metabolites are excreted in the bile. A population, pharmacokinetic sub-study, derived from study AI424007 in naive patients receiving 200, 400 or 500 mg atazanavir once daily (a clinical phase III trial of atazanavir efficacy, safety and tolerability), demonstrated the relationship between atazanavir plasma exposure (AUC and C min ) and both safety (hyperbilirubinaemia) and viral efficacy.
The meta-analysis of studies assessing a triple regimen containing unboosted atazanavir in patients with virological success suggests that switching to a triple therapy including unboosted atazanavir may be considered whatever the associated NRTI backbone (tenofovir disoproxil fumarate/emtricitabine or abacavir/lamivudine), which allows both ritonavir sparing and tenofovir disoproxil fumarate sparing in patients for whom there is concern regarding chronic renal toxicities.
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Sparing NRTIs, even when considering the last widely used generations of these agents, remains a key issue to reduce the risks of cardiovascular disease and/or nephrotoxicity. 3 While being preferentially recommended in initiation, NRTI-regimens including tenofovir disoproxil fumarate are associated with potential renal impairment. Indeed, a dose-dependent effect of tenofovir plasma concentrations on kidney tubular dysfunction has been reported, which suggests that therapeutic drug monitoring of tenofovir might be useful to prevent renal toxicity and optimize tenofovir disoproxil fumarate tolerance. 51 More recently, a high prevalence of elevated C min -tenofovir was shown to correlate with the increased risk of renal impairment. 52 Due to limited or conflicting data on long-term PI monotherapy with lopinavir/ ritonavir, atazanavir/ritonavir or darunavir/ritonavir, 3, 14, 15 a dual therapy appears as a more acceptable therapeutic option.
Based on these results, and to consider a step-by-step approach limiting the changes of the regimen, one may consider that some patients with virological suppression on cART could be maintained on a double NRTI backbone (tenofovir disoproxil fumarate/emtricitabine or abacavir/lamivudine) associated with unboosted atazanavir, while others could be maintained on a dual therapy atazanavir/ritonavir + lamivudine, depending on the patient-related context and objectives. For instance, sparing tenofovir disoproxil fumarate could be relevant in patients with bone or kidney concerns, while sparing ritonavir could be preferentially proposed to patients concerned with hyperbilirubinaemia and/or risk of nephrolithiasis, 53 and drug -drug interactions.
From data to practice
In westernized countries, most HIV-infected patients on cART achieve sustained plasma HIV suppression. Due to the dramatic increase in life expectancy of these patients, the need to lower the risk of short-or long-term toxicities associated with NRTIs or favoured by ritonavir (when considering PI/r) became an important issue. Another advantage of a maintenance therapy with LDR is the cost -benefit expected to result from such strategies. Indeed, beyond the reduced prices of regimens including atazanavir instead of atazanavir/ritonavir, or of those including atazanavir/ritonavir +generic lamivudine instead of triple therapies, the reduction of toxicity and of associated management-related costs has to be taken into account, particularly while considering long-term perspectives for patients. In that respect, atazanavirbased LDR offer the advantages of a high virological efficacy with or without ritonavir, a high genetic barrier and a good profile of tolerance with manageable adverse events mainly restricted to hyperbilirubinaemia. Thus, while having been launched several years ago and being challenged as a third agent in naive patients, atazanavir represents a credible option when a switch is considered in the context of virological success, either in dual association with lamivudine or as an unboosted PI associated with abacavir/ lamivudine or tenofovir disoproxil fumarate/emtricitabine. Regarding the choice of the NRTI to be associated with atazanavir/ritonavir, one can expect that data with emtricitabine could be similar to those obtained with lamivudine. However, because the randomized studies detailed above did not assess the association of atazanavir/ritonavir and emtricitabine, this option may not be preferentially recommended. Tenofovir disoproxil fumarate sparing is one of the main issues in terms of long-term toxicity, and other possible options are available or in clinical development. It includes new or recent INSTIs as dual regimens and the development of tenofovir alafenamide, an alternative formulation of tenofovir supposed to be less toxic for kidneys and bones as a prodrug, but with a safety profile that remains to be documented, particularly in patients with a prior history of tenofovir disoproxil fumarate nephrotoxicity. 54 So far, data are lacking regarding the long-term impact of dolutegravir or elvitegravir/cobicistat on the risk of raising HIV resistance, and a lower risk of renal toxicity with tenofovir alafenamide in a real-life setting remains to be documented. The dual association of one PI/r with one INSTI such as dolutegravir, while potentially attractive, remains limited in terms of data, so recommending this option for NRTI sparing is premature or could be restricted to specific complicated cases requiring an absolute 'no-nuke' regimen.
In conclusion, and based on the largely documented data available with atazanavir, the authors of the present paper suggest considering patients who are virologically suppressed on cART for at least 12 months, whose nadir CD4 counts are .100/ mm 3 and without previous virological failure, as candidates for a switch to an LDR. Switching to a dual therapy or a maintenance triple therapy with unboosted atazanavir is the physician's decision and no 'recipe' is (or will be) available. Factors to be taken into account include the objectives to be reached, which are based on the risks of comorbidities, kidney and cardiovascular status, co-medications and the patient's way of life. In that respect, clinicians will have to choose the regimen most appropriate for each patient depending on the therapeutic objectives and For debate JAC benefits to be achieved. Regarding specifically patients on STR, a formulation known to be very attractive when ART is initiated, the challenge will be to convince him or her that two pills are better than one. The 'therapeutic alliance' between the patient and his/ her doctor will be crucial, particularly when considering switching to a dual therapy after triple regimen prescribed for a long time, and associated with an increase in the duration of virological suppression and life expectancy. The acceptance of such a change requires a clear understanding of, and a faith in, the expected benefits.
The robustness of the data available have made the concept of LDR in patients with virological suppression turn to a feasible and reasonable option with no expected risk. While a switch to an LDR based on atazanavir and lamivudine is not expected to modify the long-term challenge of persistent immune activation and its potential impact on comorbidities, further studies aimed to assess the impact of LDR on HIV replication in compartments with limited drug penetration are warranted. In that respect, a close evaluation including viral load to check for rebounds, clinical monitoring and laboratory testing may be considered, according to what is proposed by the current guidelines regarding regimen switch in the setting of virological suppression. It is a new opportunity for physicians not to deprive patients of a better long-term quality of life.
